Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis

被引：11

作者：

Venet, Melany ^{[2
,3
]}

Lepine, Anne ^{[4
]}

Maarouf, Adil ^{[2
]}

Biotti, Damien ^{[5
,6
,7
]}

Boutiere, Clemence ^{[2
]}

Casez, Olivier ^{[8
]}

Cohen, Mikael ^{[9
]}

Durozard, Pierre ^{[10
]}

Demortiere, Sarah ^{[2
]}

Giorgi, Laetitia ^{[11
,12
]}

Maillart, Elisabeth ^{[13
]}

Mathey, Guillaume ^{[14
]}

Mazzola, Laure ^{[3
]}

Rico, Audrey ^{[2
]}

Camdessanche, Jean-Philippe ^{[3
]}

Deiva, Kumaran ^{[11
,12
]}

Pelletier, Jean ^{[2
]}

Audoin, Bertrand ^{[1
,2
]}

机构：

[1] Aix Marseille Univ, Hop Timone, AP HM, Pole Neurosci Clin,Serv Neurol, F-13005 Marseille, France

[2] Aix Marseille Univ, Hop Timone, AP HM, Dept Neurol,CNRS,CRMBM, Marseille, France

[3] Univ Hosp, Neurol Dept, St Etienne, France

[4] Hop Univ, AP HM, Paediat Neurol Dept, Marseille, France

[5] CHU Toulouse Purpan, Hop Pierre Paul Riquet, CRC SEP, Toulouse, France

[6] CHU Toulouse Purpan, Hop Pierre Paul Riquet, Serv Neurol B4, Toulouse, France

[7] Univ Toulouse 3, Inst Toulousain Malad Infect & Inflammatoires Inf, INSERM, CNRS,UMR5051,UMR1291, Toulouse, France

[8] Ctr Hosp Univ Grenoble Alpes, Neuroinflammatory Dis Ctr, Grenoble, France

[9] Univ Nice Cote dAzur, Hop Pasteur 2, CHU Nice, CRC SEP,UR2CA,URRIS, Nice, France

[10] Ctr Hosp Ajaccio, Ajaccio, France

[11] Hop Univ Paris Saclay, Hop Bicetre, Natl Reference Ctr Rare Inflammatory & Autoimmune, Dept Paediat Neurol, Le Kremlin Bicetre, France

[12] Univ Paris Saclay, UMR 1184, Immunol Viral Infect & Autoimmune Dis, Le Kremlin Bicetre, France

[13] Hop La Pitie Salpetriere, AP HP, Natl Reference Ctr Rare Inflammatory & Autoimmune, Dept Neurol, Paris, France

[14] Univ Hosp Nancy, Hop Cent, Neurol Unit, Nancy, France

来源：

MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 02期

关键词：

Pediatric onset multiple sclerosis; ocrelizumab; rituximab; RITUXIMAB;

D O I：

10.1177/13524585231223069

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Recent studies in adults suggested that extended-interval dosing of rituximab/ocrelizumab (RTX/OCR) larger than 12 months was safe and could improve safety. This was an observational cohort study of very active pediatric-onset multiple sclerosis (PoMS) (median (range) age, 16 (12-17) years) treated with RTX/OCR with 6 month standard-interval dosing (n = 9) or early extended-interval dosing (n = 12, median (range) interval 18 months (12-25)). Within a median (range) follow-up of 31 (12-63) months after RTX/OCR onset, one patient (standard-interval) experienced relapse and no patient showed disability worsening or new T2-weighted lesions. This study suggests that the effectiveness of RTX/OCR is maintained with a median extended-interval dosing of 18 months in patients with very active PoMS.

引用

页码：261 / 265

页数：5

共 18 条

[1] Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis [J].

Baroncini, Damiano ;

Simone, Marta ;

Iaffaldano, Pietro ;

Brescia Morra, Vincenzo ;

Lanzillo, Roberta ;

Filippi, Massimo ;

Romeo, Marzia ;

Patti, Francesco ;

Chisari, Clara Grazia ;

Cocco, Eleonora ;

Fenu, Giuseppe ;

Salemi, Giuseppe ;

Ragonese, Paolo ;

Inglese, Matilde ;

Cellerino, Maria ;

Margari, Lucia ;

Comi, Giancarlo ;

Zaffaroni, Mauro ;

Ghezzi, Angelo .

JAMA NEUROLOGY, 2021, 78 (06) :726-735

[2] Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis [J].

Boremalm, Malin ;

Sundstrom, Peter ;

Salzer, Jonatan .

JOURNAL OF NEUROLOGY, 2021, 268 (06) :2161-2168

[3] Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis [J].

Chitnis, Tanuja ;

Arnold, Douglas L. ;

Banwell, Brenda ;

Brueck, Wolfgang ;

Ghezzi, Angelo ;

Giovannoni, Gavin ;

Greenberg, Benjamin ;

Krupp, Lauren ;

Rostasy, Kevin ;

Tardieu, Marc ;

Waubant, Emmanuelle ;

Wolinsky, Jerry S. ;

Bar-Or, Amit ;

Stites, Tracy ;

Chen, Yu ;

Putzki, Norman ;

Merschhemke, Martin ;

Gaertner, Jutta .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (11) :1017-1027

[4]

Claverie R., 2023, Neurol Neuroimmunol Neuroinflamm, V10

[5] Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab [J].

de Flon, Pierre ;

Gunnarsson, Martin ;

Laurell, Katarina ;

Soderstrom, Lars ;

Birgander, Richard ;

Lindqvist, Thomas ;

Krauss, Wolfgang ;

Dring, Ann ;

Bergman, Joakim ;

Sundstrom, Peter ;

Svenningsson, Anders .

NEUROLOGY, 2016, 87 (02) :141-147

[6] Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care [J].

Fadda, Giulia ;

Armangue, Thais ;

Hacohen, Yael ;

Chitnis, Tanuja ;

Banwell, Brenda .

LANCET NEUROLOGY, 2021, 20 (02) :136-149

[7] What does first-line therapy mean for paediatric multiple sclerosis in the current era? [J].

Hacohen, Yael ;

Banwell, Brenda ;

Ciccarelli, Olga .

MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (13) :1970-1976

[8] B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis [J].

Hauser, Stephen L. ;

Waubant, Emmanuelle ;

Arnold, Douglas L. ;

Vollmer, Timothy ;

Antel, Jack ;

Fox, Robert J. ;

Bar-Or, Amit ;

Panzara, Michael ;

Sarkar, Neena ;

Agarwal, Sunil ;

Langer-Gould, Annette ;

Smith, Craig H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (07) :676-688

[9] Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases [J].

Khojah, Amer M. ;

Miller, Michael L. ;

Klein-Gitelman, Marisa S. ;

Curran, Megan L. ;

Hans, Victoria ;

Pachman, Lauren M. ;

Fuleihan, Ramsay L. .

PEDIATRIC RHEUMATOLOGY, 2019, 17 (01)

[10]

Krysko K, 2018, NEUROLOGY, V90

← 1 2 →